From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Breaking barriers: The role of the bone marrow microenvironment in multiple myeloma progression

Last Updated: Wednesday, August 27, 2025

The bone marrow barrier (BMB) plays a critical role in multiple myeloma (MM). BMB, composed of bone marrow endothelial cells and stromal cells, fosters the survival and growth of MM cells by secreting various supportive factors. Despite advancements in treatments, MM often relapses, primarily due to the protective microenvironment provided by the bone marrow. Key molecular interactions within the BMB that facilitate MM cell retention and resistance to therapies are identified. Targeting these interactions, especially in combination with existing immunotherapies, could lead to more effective and durable treatment outcomes.

International Journal of Molecular Sciences
Advertisement
News & Literature Highlights

The Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

American Journal of Blood Research

Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma

Cancer Epidemiology

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

Molecular and Cellular Probes

The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Journal of Translational Medicine

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

The Asco Post

Off-the-shelf CAR T-cell therapy produces deep, durable responses in heavily pretreated multiple myeloma

Cancer Medicine

Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma

BMC Infectious Diseases

Machine learning triumphs in differentiating fungal and bacterial infections

Advertisement
Advertisement